Detecting chromosomal alterations at 1p and 19q by FISH and DNA fragment analysis - A comparative study in human gliomas

Clinical Neuropathology

Volumn 27, Issue 6, 2008, Pages 378-387

  Broholm, H ^a   Born, P W ^a   Guterbaum, D ^a   Dyrbye, H ^a   Laursen, H ^a  

^a University of Copenhagen   (Denmark)

Author keywords

1p 19q; DNA fragment analysis; FISH; Gliomas

Indexed keywords

DNA FRAGMENT;

ARTICLE; ASTROCYTOMA; BRAIN CORTEX; CANCER GRADING; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME ABERRATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DNA DETERMINATION; DNA EXTRACTION; FLUORESCENCE IN SITU HYBRIDIZATION; GLIOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY AND SPECIFICITY; WORLD HEALTH ORGANIZATION;

EID: 57149117325     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/npp27378     Document Type: Article

References (28)

1. Armitage P, Gehan EA. Statistical methods for the identification and use of prognostic factors. Int J Cancer. 1974; 13: 16-36.
2. Belaud-Rotureau MA, Meunier N, Eimer S, Vital A, Loiseau H, Merlio JP. Automatized assessment of 1p36-19q13 status in gliomas by interphase FISH assay on touch imprints of frozen tumours. Acta Neuropathol. 2006; 111: 255-263.
3. Born PW, Broholm H, Laursen H. Loss of heterozygosity on chromosomes 1 and 19 in cases of primary brain tumour. Ugeskr Laeger. 2006; 168: 3813-3816.
4. Boulay JL, Miserez AR, Zweifel C, Sivasankaran B, Kana V, Ghaffari A, Luyken C, Sabel M, Zerrouqi A, Wasner M, Van ME, Tolnay M, Reifenberger G, Merlo A. Loss of NOTCH2 positively predicts survival in subgroups of human glial brain tumors. PLoS ONE. 2007; 2: e576.
5. Bouvier C, Roll P, Quilichini B, Metellus P, Calisti A, Gilles S, Chinot O, Fina F, Martin PM, Figarella-Branger D. Deletions of chromosomes 1p and 19q are detectable on frozen smears of gliomas by FISH: usefulness for stereotactic biopsies. J Neurooncol. 2004; 68: 141-149.
6. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol. 1988; 23: 360-364.
7. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pare and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006; 24: 2707-2714.
8. Eoli M, Bissola L, Bruzzone MG, Pollo B, Maccagnano C, De ST, Valletta L, Silvani A, Bianchessi D, Broggi G, Boiardi A, Finocchiaro G. Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int J Cancer. 2006; 119: 84-90.
9. Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, Schlegel U, Schramm J, Wiestler OD, Reifenberger G. Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol. 2004; 14: 121-130.
10. Hartmann C, Mueller W, Lass U, Kamel-Reid S, von Deimling A. Molecular-genetic analysis of oligodendroglial tumors. J Neuropathol Exp Neurol. 2005; 64: 10-14.
11. Hatanpaa KJ, Burger PC, Eshleman JR, Murphy KH, Berg KD. Molecular diagnosis of oligodendroglioma in paraffin sections. Lab Invest. 2003; 83: 419-428.
12. Idbaih A, Marie Y, Pierron G, Brennetot C, Hoang-Xuan K, Kujas M, Mokhtari K, Sanson M, Lejeune J, Aurias A, Delattre O, Delattre JY. Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol. 2005; 58: 483-487.
13. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Ramsay DA, Cairncross JG, Louis DN. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res. 2001; 7: 839-845.
14. Kleihues P, Cavenee WK. Pathology and genetics of tumours of the nervous system. World Health Organization Classification of Tumours (ed). Lyon: IARC Press; 2000; p 10-70.
15. Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, Louis DN, Wiestler OD, Von DA. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol. 1995; 54: 91-95.
16. Kros JM, Gorlia T, Kouwenhoven MC, Zheng PP, Collins VP, Figarella-Branger D, Giangaspero F, Giannini C, Mokhtari K, Mork SJ, Paetau A, Reifenberger G, van den Bent MJ. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol. 2007; 66: 545-551.
17. Louis DN, Cairncross JG. Specific chromosomal losses predict chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Neuropathol Exp Neurol. 1998; 57: 472.
18. McDonald JM, See SJ, Tremont IW, Colman H, Gilbert MR, Groves M, Burger PC, Louis DN, Giannini C, Fuller G, Passe S, Blair H, Jenkins RB, Yang H, Ledoux A, Aaron J, Tipnis U, Zhang W, Hess K, Aldape K. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer. 2005; 104: 1468-1477.
19. Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, Veelken J, Schramm J, Weller M, Wiestler OD, Louis DN, von Deimling A. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol. 2002; 161: 313-319.
20. Nigro JM, Takahashi MA, Ginzinger DG, Law M, Passe S, Jenkins RB, Aldape K. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol. 2001; 158: 1253-1262.
21. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. 1994; 145: 1175-1190.
22. Reifenberger G, Louis DN. Oligodendroglioma: Toward molecular definitions in diagnostic neurooncology. J Neuropathol Exp Neurol. 2003; 62: 111-126.
23. Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G, Hosek SM, Kimmel D, O'Fallon J, Yates A, Feuerstein BG, Burger PC, Scheithauer BW, Jenkins RB. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene. 1999; 18: 4144-4152.
24. Thiessen B, Maguire JA, McNeil K, Huntsman D, Martin MA, Horsman D. Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. J Neurooncol. 2003; 64: 271-278.
25. Ueki K. Oligodendroglioma: impact of molecular biology on its definition, diagnosis and management. Neuropathology. 2005; 25: 247-253.
26. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer Phase III trial. J Clin Oncol. 2006; 24: 2715-2722.
27. Watanabe T, Nakamura M, Kros JM, Burkhard C, Yonekawa Y, Kleihues P, Ohgaki H. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol. 2002; 103: 267-275.
28. Zlatescu MC, TehraniYazdi A, Sasaki H, Megyesi JF, Betensky PA, Louis DN, Cairncross JG. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res. 2001; 61: 6713-6715.